OpusPoint Partners: Investing in Biotechnology’s Future
Advancements in the areas of life science and biotechnology are what OpusPoint Partners are all about. The company encourages original development of biotechnology ideas and supports those businesses that encompass a pioneering spirit. OpusPoint Partners consistently utilizes its knowledge of both the financial and healthcare world to make a difference in human health.
OpusPoint Partners first came together in 2009; the company is the product of Michael Weiss and Lindsay Rosenwald, M.D. This is the first combined venture for Rosenwald and Weiss, though individually they have been garnered much success in the life science and biotech industries. Both men bring over 20 years experience to the company; this includes founding and financing numerous biotechnology companies of their own over the years.
For Lindsay Rosenwald, one of his most recent individually successful ventures outside of OpusPoint Partners was his formation of Cougar Biotechnology Inc. This biotech company is located in Southern California and primarily researches and develops drugs to help combat cancer. Cougar Biotech has had some success with a drug for prostate cancer and has obtained the interest of researchers and investors alike. In 2009 Johnson & Johnson took notice and purchased the company for roughly one billion dollars.
OpusPoint Partners holds steadfast to expecting its associated biotech companies to abide by Rosenwald’s and Weiss’ strong principles of ethics in research and drug trials. OpusPoint Partners specifically looks for those biotech companies who have innovative ideas and the beginning foundation of sound business standards. Maintaining a business standard that crosses the board ensures the investors that their financial support is indeed secure. This investor confidence in turn aids in the development of the emergent biotech firms operating under the guidance of OpusPoint Partners and subsequently leads to necessary breakthroughs in the healthcare industry.
Lindsay Rosenwald is considered as a mentor of sorts to those biotechnology firms that OpusPoint Partners invests in; he brings his extensive expertise into play when he assists these companies in reaching their business goals. Because he has spent over 20 years in the same industry both creating and managing in excess of 50 biotech firms during this time, Rosenwald has much to offer these budding companies in an advisory context. Even though gaining appropriate financial backing is a key aspect for any emerging company, finding a mentor who can guide you to your end goal unimpeded is just as essential.
With Lindsay Rosenwald taking the lead at OpusPoint Partners, both individual and corporate investors can breathe a sigh of relief knowing that their investments are being managed properly and that transparency in the company’s dealings are being maintained. Rosenwald’s academic knowledge and professional experience in both the healthcare and financial sectors has proven to be an asset for OpusPoint Partners and its investors. He has shown that he understands what is required for a biotech firm to succeed and lay new groundwork in the medical field and because of this know-how the company has certainly shown their investors that minimal risk and optimal growth is attainable with OpusPoint Partners.
Lindsay Rosenwald brings a lot to the OpusPoint Partners table; he has spent a total of 17 years working in both finance on Wall Street and in developing biotechnology companies. Rosenwald’s academic pursuits include receiving a Bachelor of Science in Finance from Pennsylvania State University and a Doctor of Medicine from Temple University School of Medicine.
Rosenwald’s background in finance has proven quite useful in his career. From 1994 – 2007 he managed the Aries Fund, during 2000 alone he oversaw in excess of one billion in investments toward healthcare in this fund. He also managed the investments of the Orion Fund (2002 to 2006) whose funds are dedicated exclusively to biotechnology.
OpusPoint Partners along with Lindsay Rosenwald have their goals set on finding the brightest and most progressive biotechnology companies to invest in. It is these truly unique companies that will diligently and ethically work to create new technologies and drugs that will change the face of the healthcare industry as we know it.
OpusPoint Partners is a company that stands out for all of the right reasons. The co-founders Rosenwald and Weiss have over a short two year time span built up a well respected company that abides attentively to their inner moral compass. They do no encourage cutting corners or tampering with research or clinic trials, they do however promote the idea of upholding integrity in all aspects of the business world.
Making a change in the healthcare industry is no easy task, Lindsay Rosenwald along with OpusPoint Partners activity recognize this challenge. But, he doesn’t let this hinder him from staying the course and continuing to push down barriers in the life science and biotechnology fields. OpusPoint Partners and its associates continue to keep their aspirations on the ultimate prize, eradication of disease.
Because of the companies tenacity in biotechnology it is obvious to those operating in the both the financial and healthcare sectors that OpusPoint Partners is an investing do and not an investing don’t. Lindsay Rosenwald prides the OpusPoint Partners success on the fact that investors are privy to the financial dealings of the company every step of the way and the emergent biotech firms that are backed by investors are selected for their ingenuity, growth potential, and ethical principles.
Lindsay Rosenwald is constantly pursuing new investment leads in order to continue the expansion of OpusPoint Partners and to get closer to making significant advances in healthcare. When he is not focusing on his professional pursuits, Rosenwald takes part on the Board of Directors of the Republican Jewish Coalition.
OpusPoint Partners: Breaking Down Barriers in Life Science and Healthcare
Life science and healthcare is emerging into a new phase of innovative development. This development will see a world of better quality medicine and healthcare. OpusPoint Partners strive to be vanguards of this revolutionary shift with real and solid investments into cutting-edge methods. Their vision is to see humanity with greater access to improved healthcare.
With more than 40 years of experience between the two of them, Michael S. Weiss and Dr. Lindsay Rosenwald established OpusPoint Partners in 2009. The company is one of several biotechnology companies the two men have created together, expressing real passion for the field. They have created very solid careers in biotech investment and life science.
Another company started by Dr. Lindsay Rosenwald is Cougar Biotechnology Inc., located in Los Angeles. This company is largely concentrated on conducting experimental research for cancer drugs and has attracted attention from investors and researchers alike. One drug promises good potential for the treatment of prostate cancer in its late states. On July 10, 2009, Johnson & Johnson gained Cougar Biotech Labs for about one billion dollars.
Lindsay Rosenwald and OpusPoint Partners are keenly focused on building alliances with the biotechnology and investment communities. Key to strong relationships is the practice of integrity – part and parcel of an organization’s culture and good business practice. The associations built between companies and industry leaders can benefit from the practice of integrity which ensures honest investment and open and direct disclosures.
OpusPoint Partners and Lindsay Rosenwald are teaming up with researchers, investors and corporations to form a partnership of mutual support and to seek out the same interests in disease treatment that is groundbreaking. Dr. Lindsay Rosenwald and OpusPoint Partners will look for and invest in the most hopeful research companies on the verge of making big medical discoveries.
Dr. Lindsay Rosenwald and OpusPoint Partners plan to change the nature of biotech investing. They are insisting that biotech facilities adhere to high standards of morality and ethical business practices. They are showing, by example, that with these high standards, companies can achieve fruitful rewards without ignoring their responsibilities to good quality.
And Dr. Rosenwald is not a stranger to these practices. He was a biotechnology entrepreneur for over 17 years on Wall Street. He has also been an important player in the founding and recapitalization of several life science and biotech companies. He holds two degrees, one a B.S. in Finance from Pennsylvania State University and the other an M.D. from Temple University School of Medicine.
He has plenty of experience in large-scale financial investing. From 1994 to 2007, he managed The Aries Funds and from 2002 to 2006 he managed the Orion Fund. The Aries Funds invested over $1 billion dollars in healthcare; the Orion Fund contributed funds totally to private biotechnology investments, particularly PIPEs.
OpusPoint Partners’ is founded upon the aim of creating meaningful partnerships in the world of life science and healthcare. These partnerships reflect a mutual dedication to honesty and integrity. In today’s market, this kind of conglomeration may be a rarity, as business leaders may all too often neglect ethics in their goals of obtaining positive clinical trials and higher profit.
But OpusPoint Partners plans to provide an altogether different example. It has already shown its commitment to business integrity in the treatment of its shareholders (particularly to investors and employees). It has also shown its steady stance in applying ethical integrity to the process of drug testing, manufacture and investigation.
Guided by two very competent and successful leaders, OpusPoint Partners undoubtedly has a brilliant future. The shared experience, knowledge and expertise between Michael Weiss and Dr. Lindsay Rosenwald make the two leaders more than apt in guiding the company towards revolutionary change in healthcare and medicine.
It will not be easy, though, to alter traditional attitudes to medicine and healthcare. The collective effort will require time and money well-spent and a great deal of dedication and commitment to firm ethical boundaries.
Dr. Rosenwald, though, knows this is possible. OpusPoint Partners, in a small amount of time, has made important accomplishments. It has managed to help finance more than 20 companies in less than two years. It is clear that using the best practices can certainly produce attractive and ideal results in financing and drug research.
Dr. Lindsay Rosenwald serves the Republican Jewish Coalition as one of its board directors. He also maintains strong associations with leaders in the biotechnology financing industry. OpusPoint Partners looks forward to a progressive future under his leadership guidance.